Navigation Links
Smith & Nephew Announces Breakthrough VERILAST(TM) Technology
Date:3/4/2008

Studies show a stronger and longer lasting knee

MEMPHIS, Tenn. and SAN FRANCISCO, March 4 /PRNewswire-FirstCall/ -- Smith & Nephew, Inc. (NYSE: SNN, LSE: SN) Orthopaedic Reconstruction business today announced the introduction of its VERILAST(TM) Technology. VERILAST Technology represents a technological leap forward in implant performance for knee replacement surgery. VERILAST Technology is an optimized material combination engineered specifically to improve knee implant performance and durability. This technology combines Smith & Nephew's award winning OXINIUM(TM) material with highly cross-linked polyethylene (XLPE) to produce a one-of-a-kind total knee replacement device.

"Smith & Nephew has a longstanding reputation for providing surgeons with innovative technologies designed to maximize patient outcomes," said Joseph DeVivo, president of Smith & Nephew Orthopaedic Reconstruction. "Initial data on implant wear compared to competitive systems has been very encouraging. Due to the significant improvements we are observing in wear rates over competitive material combinations, a knee with VERILAST Technology may be the only implant many patients ever receive. Combined with our award-winning OXINIUM Oxidized Zirconium, the history of innovation in implant endurance continues with the introduction of our VERILAST Technology."

In lab testing, Smith & Nephew researchers demonstrated that the composition of both articulating surfaces is critical to the performance of the entire bearing couple. When XLPE is combined with OXINIUM alloy, significant improvements in wear resistance are both provided and maintained. Smith & Nephew is the only orthopaedic manufacturer that utilizes high performance materials in both be
'/>"/>

SOURCE Smith & Nephew, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer
2. GlaxoSmithKline Responds to JAMA Articles
3. The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus
4. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
5. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
6. TIGroup Names Dennis M. Smith as Chief Financial Officer
7. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
8. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
9. Smith & Nephew Endoscopys KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries
10. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
11. Smithfield(R) LEAN GENERATION(R) Announces DELI FOR THE CURE(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...s., Dec. 1 MassMutual Retirement S...support its increasing nonprofit business. Nonprof... to last year. , , Dan Darby joined MassMu...for the Western region. He reports to M. Palmer Wh...t, for MassMutual,s Retirement Services Division, ...
(Date:12/1/2008)... may prevent cognitive decline in some, study says... Older adults who exercise regularly have increase...rain, a new study shows. , The University of No... Monday at the Radiological Society of North Ameri...lain other studies that exercise prevents cognitiv...
(Date:12/1/2008)... Dec. 1 Today, more tha...,000 people die each day due to HIV/AIDS. , ...ness and outreach to help people worldwide underst...rld AIDS Day 2008 is You Can Make a Difference ...e together to talk about HIV as well as helping di...
(Date:12/1/2008)... Dec. 1 The United Stat...his new right hand on Saturday, November 29, as Dr...eon, changed the bandages. , , "Wow, it loo... from his room at Jewish Hospital. "It,s awesome,... , Hondusky, a New York resident, went on to...
Breaking Medicine News(10 mins):Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2Health News:Fifth U.S. Hand Transplant Patient Gets Look at New Hand 2
...vement in the fight against skin cancer. A study s... of dermoscopy gives more clarity for referring pa...a study promoted by IDIBAPS-Hospital Clinic, in co...ary Care Centres. This strategy they hope could re...
...ugh to challenge a man’s decision-making skills, r...hers. // Men shown images of lingerie or sexy wome...likely to accept unfair offers. Furthermore, this ...d high testosterone levels. This study for the fi...
...outbreak of mumps over the past two decades. The c... 1988 // , is believed to have begun in late 2005 ...ials reported yesterday that the outbreak is conti...nformation from the U.S. Centres for Disease Contr...
...s whose diet was Mediterranean, that included lots...h and alcohol, and little dairy and meat, certainl...ed.// These findings have been published in the Ap...rding to stalwarts in the field of diet , Alzheime...
Other Medicine News:Health News:Dermoscopy An Able Tool For The Fight Against Skin Cancer 2Health News:Sexy Images and Lingerie Challenge A Man’s Decision Making Skill 2Health News:Mumps Outbreak In The US 2Health News:Mumps Outbreak In The US 3
(Date:11/26/2008)...Minn., Nov. 26 Children...t significantly increased risk of developing menta...s of a Mayo Clinic study published this month in ...Academy of Pediatrics. , , The retrospectiv...ts with strabismus (misaligned eyes) and compared ...
(Date:11/25/2008)...eal most respondents against expanding statin use ...LITTLE FALLS, N.J., Nov. 25 JUPITE...wer the cardiovascular risk of healthy patients wi...n use in older adults, according to a national pol...ticipants took part in the online poll conducted b...
(Date:11/25/2008)...Nov. 25 CardioVascular,...announced today that it has,dosed the first patie...e II,clinical trial to treat patients with severe...for the treatment of CORonary heart Disease) trial...ebo-controlled doses in approximately 120,patient...
(Date:11/24/2008)...ffirms its innovation leadership and long-term com...H, N.J., Nov. 24 Scherin... a clinical update on boceprevir, its lead investi...ntly in Phase III development. The company believ...lass and best-in-class protease inhibitor for trea...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Direct From Beijing 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awarene 25475 1Direct From Beijing 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awarene 25475 2Direct From Beijing 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awarene 25475 3UHW Healthcare Workers to Strike at Five Hospitals 25473 1NUCRYST Receives Deficiency Notice from NASDAQ 25471 1NUCRYST Receives Deficiency Notice from NASDAQ 25471 2NUCRYST Receives Deficiency Notice from NASDAQ 25471 3Experiments could lead to new treatments for neuroblastoma 25470 1Experiments could lead to new treatments for neuroblastoma 25470 2Experiments could lead to new treatments for neuroblastoma 25470 3
... March 26, 2007 /PRNewswire/ -- CSL Limited today,...urnal of the,American Medical Association that sug...utely raise HDL ("good" cholesterol) levels,may r...s of,patients with a recent episode of acute coron...ribe unstable angina and myocardial,infarction (he...
...(BUSINESS WIRE)--Mar 26, 2007 - Two-year results f...nfirm the positive,clinical profile of the Endeavo...ly 1,300 the number of Endeavor patients who have ...ong those 1,300,Endeavor patients, there have been...the independent, pre-specified clinical trial,prot...
Other Medicine Technology:CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 2CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 3CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries 4Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3
...gh continuous low-flow nebulizer performance. Pate...ogy allows for optimal medication and Heliox deliv...n severe asthma, COPD and pneumonia in both routin...ask, mouth and T-piece to deliver high-output, low...
... nebulizer achieves optimum lung penetration for m...le size range is 1.04-1.10 µ at 6-8 LPM. Lat...outlet., ,As the world leader in airway managemen... assurance of proven technology by offering top br...
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy.
...hift, modified nebulizer setups to deliver CNT and...patient is critical? OMNI~MAX has everything you n.... In severe obstructive disease, Heliox therapy is...cross the nation. Combine high performing continuo...
Medicine Products: